tellmeaboutpeptides
FOR RESEARCH AND EDUCATIONAL PURPOSES ONLY · NOT MEDICAL ADVICE · CONSULT A LICENSED PHYSICIAN
← Library

Fat Loss & Metabolic

Retatrutide (RETA)

Also known as LY3437943, triple agonist, GGG tri-agonist

An investigational once-weekly injection from Eli Lilly that activates three gut and pancreatic hormone receptors at once and produced the largest weight reductions yet reported in obesity trials.

How it works

The "Triple Agonist" (GLP-1 / GIP / Glucagon). Suppresses hunger while Glucagon increases energy expenditure through thermogenesis.

Performance edge

Most potent fat-loss compound in clinical trials; uniquely targets liver and visceral fat.

Plain-English guide

Retatrutide, without the jargon

What it is

Retatrutide is a single laboratory-made peptide that switches on three different hormone receptors at the same time: the GLP-1 receptor (glucagon-like peptide-1, the target of semaglutide), the GIP receptor (glucose-dependent insulinotropic polypeptide, the second target of tirzepatide) and the glucagon receptor, which no approved obesity drug currently activates. It is given as a once-weekly injection under the skin. Eli Lilly, which developed it under the code LY3437943, has run it through phase 1, phase 2 and now phase 3 trials in obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnoea, fatty liver disease and chronic kidney disease. As of September 2026 it is not approved by any regulator anywhere, so every vial outside a clinical trial or Eli Lilly's single-patient expanded access programme comes from an unregulated supply chain.

What people use it for

  • Weight reduction in adults with obesity or overweight, the indication with the most published data
  • Blood-sugar control in adults with type 2 diabetes, where it lowered HbA1c by up to 1.94 percentage points in a phase 3 trial
  • Lowering blood pressure and non-HDL cholesterol as a side effect of the metabolic changes
  • Trials in progress for knee osteoarthritis pain, obstructive sleep apnoea and chronic kidney disease alongside obesity
  • Research interest in liver and visceral fat, since the glucagon arm drives hepatic fat mobilisation

How it works, simply

Think of your appetite and your metabolism as a building with three separate control panels. Semaglutide presses one panel, tirzepatide presses two, and retatrutide presses all three. The first two panels turn hunger down and insulin up when you eat; the third, the glucagon panel, tells your liver to release stored fuel and nudges your resting energy use upward. Pressing all three at once is why the weight curves in the trials kept falling further than with earlier drugs, and also why the side-effect burden and the heart-rate response are larger.

What to expect, and when

  1. Week 1-4Most trial arms start low and escalate, typically from 2 mg, though the phase 2 obesity trial also ran a fixed 1 mg arm and the phase 1b started at 0.5 mg. Nausea and other gut symptoms are most likely around each step up, and weight change at this point is small.
  2. Week 4-12Doses are escalated every four weeks. Appetite suppression becomes obvious and the weight curve steepens. Heart rate rises in a dose-dependent way during this period.
  3. Week 24The phase 2 obesity trial measured its primary endpoint here: mean weight loss of 7.2 percent on 1 mg rising to 17.5 percent on 12 mg, against 1.6 percent on placebo. Heart-rate increases peaked around this point and then declined.
  4. Week 40-48In the phase 2 obesity trial weight loss at 48 weeks reached 8.7 percent on 1 mg and 24.2 percent on 12 mg. In the phase 3 TRANSCEND-T2D-1 diabetes trial, 40 weeks produced 11.5 to 15.3 percent weight loss and HbA1c falls of 1.69 to 1.94 percentage points.
  5. Week 80-104The phase 3 TRIUMPH-1 trial ran its main weight endpoint to week 80 with an extension to week 104. It completed in 2026, but results have not been posted on ClinicalTrials.gov, so published long-term numbers are not yet available.

Side effects and interactions

  • Gastrointestinal events are the dominant problem: nausea, vomiting, diarrhoea and constipation, dose-related, mostly mild to moderate, and partly reduced by starting at 2 mg instead of 4 mg
  • Dose-dependent increases in heart rate, which peaked around week 24 in the phase 2 obesity trial and then declined; retatrutide increases contractile force in isolated human heart tissue through its own receptors
  • Reduced appetite and early satiety, which is the intended effect but was recorded as an adverse event in the dose-escalation studies
  • Discontinuation for adverse events in 2 to 5 percent of participants in the phase 3 diabetes trial
  • No severe hypoglycaemia was reported in the phase 2 or phase 3 diabetes trials; two deaths occurred in the 4 mg group of TRANSCEND-T2D-1 and were judged unrelated to the drug
  • Grey-market product risk: three Australian samples sold as retatrutide contained 51 to 190 percent of the labelled peptide quantity, so the dose actually injected may bear little relation to the dose intended

Who should avoid it

  • You are pregnant, trying to conceive or breastfeeding, since no human pregnancy data has been published for retatrutide
  • You have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, the standing contraindication for the approved incretin drugs in this class
  • You have type 1 diabetes; a published case report describes impending diabetic ketoacidosis in a person with type 1 diabetes who used online-sourced retatrutide
  • You have a history of pancreatitis, gallbladder disease, gastroparesis or an eating disorder
  • You have an arrhythmia or other condition in which a sustained rise in heart rate matters, given the dose-dependent heart-rate increases seen in the trials
  • You are not under the supervision of a physician who can monitor weight, blood sugar, heart rate, hydration and existing medications

Common mistakes

  • Skipping the escalation schedule. Every published trial started at a low dose and stepped up every four weeks, and the gastrointestinal event rate tracked the size of each step
  • Assuming the vial contains what the label says. The Australian analysis found labelled 10 mg vials holding between 5.13 mg and 19.0 mg of peptide, which turns a planned dose into a guess
  • Reconstituting with the wrong diluent or shaking the vial. Bacteriostatic water run slowly down the vial wall and swirled, not shaken, is the standard handling for lyophilised peptides
  • Leaving the reconstituted vial at room temperature or in a car. Reconstituted peptide belongs refrigerated and protected from light
  • Stacking it with another GLP-1 or GIP drug, or letting rapid weight loss run without protein intake and resistance training. The pathways overlap, the gastrointestinal burden adds and no published human trial has tested that combination, and blood sugar needs tracking throughout if you are already on insulin or a sulfonylurea

Deep research

What the literature actually shows

Mechanism

Retatrutide (LY3437943) is a single peptide with agonist activity at three class B G-protein-coupled receptors: the glucagon receptor, the GIP receptor (glucose-dependent insulinotropic polypeptide) and the GLP-1 receptor (glucagon-like peptide-1). Approved incretin drugs in this class stop at one receptor (semaglutide) or two (tirzepatide). Adding glucagon receptor agonism is the design choice that distinguishes retatrutide, because glucagon acts mainly on the liver and on energy expenditure rather than on appetite.

The GLP-1 and GIP arms reproduce the familiar incretin effect: glucose-dependent insulin secretion, slowed gastric emptying and central appetite suppression. That combination accounts for most of the food-intake reduction. The phase 1b multiple-ascending-dose trial in people with type 2 diabetes showed the metabolic effect appearing early, with placebo-adjusted mean daily plasma glucose falling by 2.8 to 3.1 mmol/L and body weight falling up to 8.96 kg over 12 weeks at the highest doses.

The glucagon arm works in the opposite direction on the liver, promoting hepatic glucose output and fat mobilisation while raising resting energy expenditure. Pairing it with two incretin agonists is intended to let the thermogenic and hepatic effects of glucagon operate while the GLP-1 and GIP signalling holds blood glucose down and suppresses the compensatory increase in appetite. The consistently larger weight reductions in the phase 2 obesity trial compared with published single- and dual-agonist trials are the clinical expression of that design, though no head-to-head trial against tirzepatide has been published.

The same receptors are present in the heart, which is the likely explanation for the dose-dependent heart-rate increases observed in the trials. In isolated human atrial preparations taken from cardiac surgery patients, retatrutide increased force of contraction from 10 nM in a concentration- and time-dependent way, and the effect ran through cyclic AMP signalling via the glucagon, GIP and GLP-1 receptors rather than through beta-adrenergic pathways.

Strength of evidence

Human trialsMultiple randomised controlled human trials of retatrutide itself exist, including two phase 2 trials, a phase 1b dose-escalation trial and a completed phase 3 trial, all using the same once-weekly subcutaneous route as the cheatsheet protocol; the cheatsheet's 1 to 2 mg sits at the bottom of the studied range rather than outside it - the phase 2 obesity trial's 1 mg arm lost 7.2 percent of body weight at 24 weeks and 8.7 percent at 48, against 17 to 24 percent in the 8 and 12 mg arms - and the phase 3 obesity outcome data have not yet been published in a peer-reviewed journal.

Key studies

Safety data

Tolerability is dominated by the gastrointestinal tract. Across the phase 1b, phase 2 and phase 3 trials, nausea, vomiting, diarrhoea and constipation were the most common adverse events, were clearly dose-related, and were mostly mild to moderate. The phase 2 obesity trial found that a lower starting dose partly mitigated them. In TRANSCEND-T2D-1, 2 to 5 percent of participants stopped treatment because of adverse events; two deaths occurred in the 4 mg group and were judged unrelated to the drug, and no severe hypoglycaemia was recorded in either diabetes trial.

The cardiac signal deserves attention. The phase 2 obesity trial recorded dose-dependent increases in heart rate that peaked around week 24 and then declined. Work in isolated human atrial preparations shows that retatrutide raises force of contraction from 10 nM through cyclic AMP signalling at its own three receptors, which gives a plausible mechanism rather than an incidental association. The long-term cardiovascular consequence is unknown; a dedicated cardiovascular and kidney outcomes trial is running but has not reported.

The largest practical risk is not the molecule but the supply. Retatrutide is not approved by any regulator, so there is no label, no contraindication list, no pharmacovigilance database and no manufacturing standard for material bought outside a trial. The FDA states that retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition. Chemical analysis of three Australian consumer products found authentic peptide but quantities ranging from 51 percent to 190 percent of the labelled 10 mg, and a published case report describes impending diabetic ketoacidosis in a person with type 1 diabetes using online-sourced retatrutide.

Regulatory status

FDA
As of 19 September 2026 retatrutide is not approved by the FDA for any indication; it remains investigational in Eli Lilly's phase 3 TRIUMPH and TRANSCEND programmes with a single-patient expanded access route open, and the FDA states that retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition.
WADA
Retatrutide is not named individually on the WADA 2026 Prohibited List, but because no governmental regulatory health authority has approved it for human therapeutic use it falls under section S0, Non-Approved Substances, which prohibits such substances at all times in and out of competition; a 2026 analytical study reports a plasma detection window of roughly 56 days after a first dose, so athletes should treat it as prohibited and confirm status with their anti-doping organisation.
Source
https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Open questions

  • What do the phase 3 TRIUMPH obesity results actually show? TRIUMPH-1 completed in 2026 but no peer-reviewed publication or posted registry result set exists yet, so the long-term weight and safety numbers remain unverified outside sponsor statements.
  • How does retatrutide compare directly with tirzepatide or semaglutide? No head-to-head randomised trial against a dual agonist has been published, so the value of adding glucagon receptor agonism is inferred across trials rather than measured within one.
  • What are the long-term cardiovascular consequences of the dose-dependent heart-rate rise and the direct inotropic effect at cardiac receptors? The outcomes trial designed to answer this has not reported.
  • How much of the weight lost is fat versus lean mass over 80 to 104 weeks, and what happens to weight, appetite and glycaemic control after the drug is stopped? No published withdrawal or maintenance data exists.
  • Does the glucagon arm deliver the hepatic and visceral fat benefit it is designed for, and does that translate into resolution of fatty liver disease? Trials in that population are ongoing without published outcome data.

Also in Fat Loss & Metabolic

5-Amino-1MQ5 mg · DailyAOD-9604 / HGH Frag (176-191)300mcg-500mcg · DailyCagrilintide0.3mg (Titrated) · WeeklyHGH Frag250mcg-500mcg · Daily